Summary
Other Scenarios:
- ICLR - SNGX
- SNGX - PDLI
| Buyer: | Icon PLC (ICLR) | Last Price: | 21.79 | Market Cap.: | 1.32B |
|---|---|---|---|---|---|
| Target: | PDL Biopharma Inc (PDLI) | Last Price: | 6.18 | Market Cap.: | 863.93M |
Lines of Business Summary:
- Icon PLC (ICLR) competes in 1 industry and 9 product/service groups
- PDL Biopharma Inc (PDLI) competes in 1 industry and 26 product/service groups
- A combined entity will have 0% Product/Service Group overlap
- Icon PLC (ICLR) has 0 and PDL Biopharma Inc (PDLI) has 2 customers that derive significant revenue from each. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
Healthcare |
|
|
732 |
Biopharmaceuticals |
|
334 | |
|
Healthcare Services |
|
122 | |
|
Outsourced Biomedical Services |
|
|
39 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 16)
|
Target (Total: 10)
|
Buyer
|
Target
|
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 1)
|
Target (Total: 1)
|
Buyer (Total: 5)
|
Target (Total: 8)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 7,720 | 8 |
| Revenue Per Employee | 120,845.6 | 61,231,260.0 |
| Total Revenue | 252.3 | 77.3 |
| Total Expenses | 240.6 | 6.9 |
Other Revenue
|
n/a | n/a |
|
Cost of Revenue
|
162.3 | n/a |
|
SG&A Expense
|
67.5 | n/a |
|
Research & Development
|
n/a | n/a |
|
Other Operating Expense
|
n/a | n/a |
|
Operating Income
|
11.7 | 70.4 |
|
Unusual Income
|
n/a | n/a |
|
LT Debt to Capital
|
n/a | n/a |
|
Fwd P/E
|
22.24 | 4.32 |
|
Fwd P/Rev
|
1.21 | 2.29 |
| Book Value | 701.8 | -243.8 |
|
Curr Portion of LTD/Cap Lease
|
n/a | 69.5 |
Individual Company Summary
Focused
Buyer
Focused ():
Healthcare > Outsourced Biomedical Services > Development/Manufacturing Services > Contract Research Organizations (CRO) > Limited Service > Clinical
Target
Focused ():
Healthcare > Outsourced Biomedical Services > Drug Discovery Services > Lead Discovery/Validation/Optimization > Lead Biologics > Antibodies
Business Description
Buyer
ICON public limited company (ICON) is a contract research organization (CRO), providing outsourced development services on a global basis to the pharmaceutical, biotechnology and medical device industries. The Company specializes in the development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. During the year ended December 31, 2010, the Company operated in 73 locations in 39 countries, providing Phase I-IV clinical trial management, drug development support services, data management and biostatistical, central laboratory, imaging and contract staffing services. On January 14, 2011 the Company acquired 80% interest Oxford Outcomes Limited, an international health outcomes consultancy with offices in the United States and Canada. On May 17, 2010 the Company acquired Timaq Medical Imaging AG. In July 2011, the Company acquired Firecrest Clinical.
Target
PDL BioPharma, Inc. (PDL) is engaged in the management of its antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with pharmaceutical and biotechnology companies. The Company receives royalties based on these license agreements on sales of a number of humanized antibody products marketed and also may receive royalty payments on additional humanized antibody products launched before final patent expiry in December 2014. The Company has entered into licensing agreements with numerous entities that are independently developing or have developed humanized antibodies pursuant to which it has licensed certain rights under its Queen et al. patents to make, use, sell, offer for sale and import humanized antibodies. It receives royalties on net sales of products that are made, used or sold prior to patent expiry. In general, these agreements cover antibodies targeting antigens specified in the license agreements.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
35 | 100 |
|
Operating Margin %
|
3.12 | 97.61 |
|
Quick Ratio
|
n/a | 1.26 |
|
Current Ratio
|
n/a | 1.38 |
|
Coverage Ratio
|
n/a | n/a |
| Total Assets | 1,125.5 | 235.0 |
| Return on Equity % | 13.4 | n/a |
| Return on Assets % | 8.35 | 197.31 |
|
Cash+ ST Inv. Per Share
|
3.06 | 1.12 |
| Total Debt | 0.0 | 398.6 |
| Total Debt to Equity % | 0 | 0 |
| Total Debt to Tangible Equity % | 0 | n/a |
|
Debt to Asset %
|
0.00 | 169.66 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
Biopharmaceuticals |
|
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
|
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
|
|
|
|
Healthcare Services |
|
|
|
Healthcare Support Services
The Support Services Subsector is comprised of companies that provide non-medical services for managing, enhancing, facilitating, and enabling the healthcare delivery process.
|
|
|
|
Outsourced Biomedical Services |
|
|
|
Analytical Services
The Analytical Services Subsector includes outsourced services that utilize analytical instruments to analyze biological and chemical samples.
Buyer Products:
|
|
|
|
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
|
|
|
|
Drug Discovery Services
The Drug Discovery Services Subsector includes companies that provide biopharmaceutical companies with novel biological targets and drug leads.
|
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
Allergies |
|
|
Upper Respiratory |
|
|
|
Monoclonal Antibodies
Therapeutics that treat allergic reactions by specifically binding and inhibiting inflammatory substances.
Target Products:
|
|
|
|
Digestive System |
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Intestinal Disorders |
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Crohn`s Disease |
|
|
|
Alpha 4 Integrin Inhibitors
Therapeutics that prevent/inhibit the inflammation process by blocking the action of integrin, molecules involved in the inflammation process.
Target Products:
|
|
|
|
Hematology |
|
|
|
Red Blood Cell (RBC) Disorders |
|
|
|
Hemoglobinuria |
|
|
|
Monoclonal Antibodies
Therapeutics that treat hemoglobinuria by specifically binding to the C5 complement component and inhibiting its activation.
Target Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Arthritis |
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Immunotherapy |
|
|
|
Monoclonal Antibodies
Therapeutics that treat rheumatoid arthritis by interfering with specific immune pathways implicated in the progression of the disease.
Target Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Crohn`s Disease |
|
|
|
Alpha 4 Integrin Inhibitors
Therapeutics that prevent/inhibit the inflammation process by blocking the action of integrin, molecules involved in the inflammation process.
Target Products:
|
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Alpha 4 Integrin Inhibitors
Therapeutics that prevent/inhibit the inflammation process by blocking the action of integrin, molecules involved in the inflammation process.
Target Products:
|
|
|
|
Immune Deficiency Disorders |
|
|
|
Atypical Hemolytic Uremic Syndrome (aHUS) |
|
|
|
Monoclonal Antibodies
Therapeutics that treat Atypical Hemolytic Uremic Syndrome by specifically binding certain receptors implicated with the disease.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.
Target Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Skeletal Disorders |
|
|
|
Joint Disorders |
|
|
|
Ankylosing Spondylitis |
|
|
|
Immunotherapy |
|
|
|
Monoclonal Antibodies
Therapeutics that treat ankylosing spondylitis interfering with specific immune pathways implicated in the progression of the disease.
Target Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Immunotherapy |
|
|
|
Monoclonal Antibodies
Therapeutics that treat rheumatoid arthritis by interfering with specific immune pathways implicated in the progression of the disease.
Target Products:
|
|
|
|
Neurology |
|
|
|
Neuromuscular Disorders |
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Alpha 4 Integrin Inhibitors
Therapeutics that prevent/inhibit the inflammation process by blocking the action of integrin, molecules involved in the inflammation process.
Target Products:
|
|
|
|
Oncology |
|
|
|
Breast Cancer |
|
|
|
Localized |
|
|
|
Monoclonal Antibodies
Therapeutics that treat breast cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Target Products:
|
|
|
|
Metastatic |
|
|
|
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of breast cancer cells and inhibit the cancer cells' growth and induce their death.
Target Products:
|
|
|
|
Digestive System |
|
|
|
Colon Cancer/Colorectal Cancer |
|
|
|
Metastatic |
|
|
|
Monoclonal Antibodies
Therapeutics that treat colorectal cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Target Products:
|
|
|
|
Gastric Cancer (Stomach Cancer) |
|
|
|
Metastatic |
|
|
|
Monoclonal Antibodies
Therapeutics that treat gastric cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Target Products:
|
|
|
|
Neurology |
|
|
|
Brain Cancer |
|
|
|
Glioma |
|
|
|
Glioblastoma |
|
|
|
Monoclonal Antibodies
Therapeutics that treat and manage tumors of the glial cells by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.
Target Products:
|
|
|
|
Respiratory System/Thoracic |
|
|
|
Lung Cancer |
|
|
|
Non Small Cell Lung Cancer (NSCLC) |
|
|
|
Monoclonal Antibodies
Therapeutics that treat lung cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Target Products:
|
|
|
|
Urology |
|
|
|
Kidney Cancer (Renal Cell Carcinoma) |
|
|
|
Metastatic |
|
|
|
Monoclonal Antibodies
Therapeutics that treat kidney cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Target Products:
|
|
|
|
Ophthalmology |
|
|
|
Degenerative Disorders |
|
|
|
Edema |
|
|
|
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Therapeutics that treat macular edema by binding to the vascular endothelial growth factor (VEGF) and inhibiting the formation of blood vessels in the eye.
Target Products:
|
|
|
|
Macular Degeneration (AMD) |
|
|
|
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Therapeutics that treat macular degeneration by binding to the vascular endothelial growth factor (VEGF) and inhibiting the formation of blood vessels in the eye.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Respiratory System |
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
Asthma |
|
|
|
Prophylactic Treatments |
|
|
|
Monoclonal Antibodies
Therapeutics that treat asthma with monoclonal antibodies.
Target Products:
|
|
|
|
Transplantation |
|
|
|
Renal (Kidney) |
|
|
|
Rejection Prophylaxis |
|
|
|
Monoclonal Antibodies
Protein-based therapeutics that target specific substances like proteins.
Target Products:
|
|
|
|
Healthcare Services |
|
|
|
Healthcare Support Services |
|
|
|
Consulting
Services providing advice, assistance, and information to a wide range of healthcare companies, including pharmaceutical, medical devices, and health services companies.
Buyer Products:
|
|
|
|
Staffing/Recruiting |
|
|
|
Clinical |
|
|
|
Health Professionals
Staffing and recruiting of health professionals directly involved in the healthcare delivery process (i.e. physicians, physical therapists, occupational therapists, etc.).
Buyer Products:
|
|
|
|
General
Staffing and recruiting of personnel that are not directly involved with the delivery of healthcare but that are part of the overall healthcare delivery process (I.e. Hospital administrators, medical office staff, etc.).
Buyer Products:
|
|
|
|
Outsourced Biomedical Services |
|
|
|
Analytical Services
The Analytical Services Subsector includes outsourced services that utilize analytical instruments to analyze biological and chemical samples.
Buyer Products:
|
|
|
|
Development/Manufacturing Services |
|
|
|
Contract Research Organizations (CRO) |
|
|
|
Full Service
Contract Research Organizations (CROs) that conduct both preclinical and clinical studies in the development of new therapeutic products.
Buyer Products:
|
|
|
|
Limited Service |
|
|
|
Clinical
Limited Service Contract Research Organizations that design, manage, and monitor human studies of new therapeutics. Other services include project management, patient recruitment, data management, biostatistical analysis, medical and regulatory affairs, and quality assurance.
Buyer Products:
|
|
|
|
Preclinical
Limited Service Contract Research Organizations that design, manage, and monitor animal studies of new therapeutics. In addition to animal studies, these limited service companies also provide formulation development services.
Buyer Products:
|
|
|
|
Drug Discovery Services |
|
|
|
Lead Discovery/Validation/Optimization |
|
|
|
Assay Development
Bioanalytical services that are used to develop biologically based tests for use in high throughput screening (HTS).
Buyer Products:
|
|
|
|
Lead Biologics |
|
|
|
Antibodies
Biological lead compounds which have a specific amino acid sequence that only interacts with specific substances to cause an immunological response.
Target Products:
|
|
|
|
Proteins
Biological based lead compounds composed of amino acids.
Buyer Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
Pharmaceutical Product Development Inc
|
|
n/a | 3,785.883 | 22.98 | n/a | 2.37 | n/a | n/a | |
|
Covance Inc
|
|
n/a | 2,709.185 | 20.47 | 16.97 | 1.19 | 1.24 | 2.44 | |
|
Parexel International Corp
|
|
n/a | 1,486.517 | 33.88 | 24.51 | 0.98 | 1.09 | 2.49 | |
|
Kendle International Inc
|
|
n/a | 228.051 | n/a | n/a | 0.53 | n/a | n/a | |
|
VirtualScopics Inc
|
|
n/a | 31.071 | 215.89 | 54.00 | 2.17 | n/a | 4.79 | |
|
Encorium Group Inc
|
|
n/a | 0.379 | n/a | n/a | 0.02 | n/a | n/a | |
|
Quintiles Transnational Corp.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
PharmaNet Development Group Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
Soligenix Inc
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Medidata Solutions Inc
|
|
n/a | 666.218 | 16.54 | 31.29 | 3.43 | 3.13 | 6.99 | |
| Target | |||||||||
|
Roche Holding AG
|
|
n/a | 139,114.120 | 24.15 | 10.09 | 2.04 | 2.93 | n/a | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Pfizer Inc
|
|
n/a | 176,093.984 | 12.76 | 10.21 | 1.76 | 2.93 | n/a | |
|
Bristol Myers Squibb Co
|
|
n/a | 55,809.424 | 14.67 | 16.79 | 2.60 | 3.12 | 11.82 | |
| Buyer | |||||||||
|
Pfizer Inc
|
|
n/a | 176,093.984 | 12.76 | 10.21 | 1.76 | 2.93 | n/a | |
|
Bristol Myers Squibb Co
|
|
n/a | 55,809.424 | 14.67 | 16.79 | 2.60 | 3.12 | 11.82 | |
|
Eli Lilly & Co
|
|
n/a | 46,816.943 | 10.86 | 12.39 | 1.95 | 2.07 | 4.89 | |
|
Sunesis Pharmaceuticals Inc
|
|
n/a | 122.857 | n/a | -3.28 | 122.69 | 193.08 | 8.37 | |
|
Tianjin Tasly Pharmaceutical Co Ltd
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
Roche Holding AG
|
|
86.00% | 139,114.120 | 24.15 | 10.09 | 2.04 | 2.93 | n/a | |
|
Elan Corporation PLC
|
|
10.00% | 7,657.835 | 16.83 | -325.00 | 6.27 | 6.23 | 15.28 | |
|
Pfizer Inc
|
|
n/a | 176,093.984 | 12.76 | 10.21 | 1.76 | 2.93 | n/a | |
|
Novartis SA
|
|
n/a | 142,003.622 | 16.43 | 9.70 | 2.40 | 2.46 | 101.58 | |
|
Bristol Myers Squibb Co
|
|
n/a | 55,809.424 | 14.67 | 16.79 | 2.60 | 3.12 | 11.82 | |
|
Biogen IDEC Inc
|
|
n/a | 31,914.176 | 25.95 | 21.64 | 6.21 | 6.01 | 9.58 | |
|
Alexion Pharmaceuticals Inc
|
|
n/a | 15,548.506 | 79.48 | 54.07 | 18.04 | 14.25 | 57.17 | |
|
EKR Therapeutics, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Microsoft Corp
|
|
n/a | 245,231.846 | 10.50 | 10.93 | 3.36 | 3.35 | 5.31 | |
|
Oracle Corp
|
|
n/a | 129,727.839 | 18.00 | 11.27 | 2.40 | 3.58 | n/a | |
|
EMC Corp
|
|
n/a | 51,499.753 | 20.19 | 17.45 | 2.51 | 2.37 | 8.41 | |
|
Phase Forward Incorporated
|
|
n/a | 743.225 | 125.94 | n/a | 3.35 | n/a | n/a | |
|
Medidata Solutions Inc
|
|
n/a | 666.218 | 16.54 | 31.29 | 3.43 | 3.13 | 6.99 | |
|
Corcept Therapeutics Inc
|
|
n/a | 326.709 | n/a | -10.08 | n/a | 21.07 | 8.31 | |
|
Tigermed Consulting Co.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
MedAvante
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Proteome Sciences
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
Pfizer Inc
|
|
n/a | 176,093.984 | 12.76 | 10.21 | 1.76 | 2.93 | n/a | |
|
Novartis SA
|
|
n/a | 142,003.622 | 16.43 | 9.70 | 2.40 | 2.46 | 101.58 | |
|
Roche Holding AG
|
|
n/a | 139,114.120 | 24.15 | 10.09 | 2.04 | 2.93 | n/a | |
|
Bristol Myers Squibb Co
|
|
n/a | 55,809.424 | 14.67 | 16.79 | 2.60 | 3.12 | 11.82 | |
|
Biogen IDEC Inc
|
|
n/a | 31,914.176 | 25.95 | 21.64 | 6.21 | 6.01 | 9.58 | |
|
Alexion Pharmaceuticals Inc
|
|
n/a | 15,548.506 | 79.48 | 54.07 | 18.04 | 14.25 | 57.17 | |
|
Elan Corporation PLC
|
|
n/a | 7,657.835 | 16.83 | -325.00 | 6.27 | 6.23 | 15.28 | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 968.8 | 645.3 | 1,614.0 |
|
Other Revenue
|
n/a | n/a | n/a |
| Total Revenue | 968.8 | 645.3 | 1,614.0 |
|
Cost of Revenue
|
629.7 | n/a | 629.7 |
|
SG&A Expense
|
263.5 | 7.7 | 271.2 |
|
Depreciation & Amortization
|
40.5 | 0.0 | 40.5 |
|
Interest Expense
|
n/a | n/a | n/a |
|
Other Operating Expense
|
n/a | n/a | n/a |
|
Unusual Expense (Income)
|
4.8 | 0.8 | 5.6 |
| Total Expenses | 938.6 | 15.4 | 954.0 |
|
Operating Income
|
30.2 | 629.8 | 660.0 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
-0.5 | -9.0 | -9.6 |
|
Other, Net
|
n/a | n/a | n/a |
| Income Before Taxes | 29.7 | 548.1 | 577.8 |
| Income Taxes | 6.2 | 192.6 | 198.8 |
| Income After Taxes | 23.5 | 115.9 | 139.4 |
|
Net Income - Excl. Xord. Items
|
23.5 | 115.9 | 139.4 |
|
Net Income - Incl. Xord. Items
|
23.5 | 115.9 | 139.4 |
|
Income Avail. to Common
|
23.5 | 115.9 | 139.4 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
60.1 | 139.7 | 199.8 |
|
Basic EPS - Excl. Xord. Items
|
0.39 | 0.83 | 0.70 |
|
Basic EPS - Incl. Xord. Items
|
0.39 | 1.12 | 0.70 |
| Full Dilution Adjustment | n/a | 0.8 | 0.8 |
| Fully Diluted Shares Outstanding | 60.7 | 167.0 | 227.7 |
|
F.D. EPS - Excl. Xord. Items
|
0.39 | 0.66 | 0.61 |
|
F.D. EPS - Incl. Xord. Items
|
0.39 | 0.95 | 0.61 |
| Dividends Per Common Share | n/a | 0.75 | 0.75 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
186.0 | 141.4 | 327.4 |
|
ST Investments
|
n/a | 46.0 | 46.0 |
|
Accounts Receivable
|
308.2 | 0.6 | 308.8 |
|
Inventory
|
n/a | n/a | n/a |
|
Prepayments and Advances
|
n/a | 8.1 | 8.1 |
|
Other Current Assets
|
133.2 | 10.7 | 144.0 |
|
Current Assets
|
n/a | 206.2 | 206.2 |
|
Accum D&A
|
n/a | n/a | n/a |
|
PPE, Net
|
n/a | 0.0 | 0.0 |
| Goodwill & Intangibles | n/a | n/a | n/a |
| Long Term Investments | n/a | 5.1 | 5.1 |
| Other Assets | n/a | n/a | n/a |
|
Other LT Assets
|
n/a | 16.2 | 16.2 |
| Total Assets | 1,125.5 | 235.0 | 1,360.5 |
| Liabilities | |||
| Accounts Payable | n/a | 0.5 | 0.5 |
| Payable/Accrued | n/a | n/a | n/a |
| Accrued Expenses | n/a | 39.1 | 39.1 |
|
ST Debt
|
n/a | n/a | n/a |
|
Curr Port of LTD & Cap Lease Oblg
|
n/a | 69.5 | 69.5 |
| Other (Current) Liabilities | 168.8 | 24.7 | 193.5 |
|
Current Liab.
|
n/a | 149.6 | 149.6 |
|
LT Debt
|
n/a | 329.1 | 329.1 |
|
Total LT Debt
|
n/a | 340.7 | 340.7 |
|
Other LT Liab.
|
n/a | n/a | n/a |
|
Total Liabilities
|
n/a | 473.7 | 473.7 |
| Shareholders Equity | |||
| Common Stock | 0.0 | 1.4 | 1.4 |
| Additional Paid in Capital | n/a | -234.8 | -234.8 |
| Retained Earnings | n/a | -1.9 | -1.9 |
| Other Equity | 681.5 | -8.5 | 673.0 |
|
Total Equity
|
701.8 | -243.8 | 458.0 |
|
Total Liab. & Equity
|
n/a | 230.0 | 230.0 |
|
Shares Outstanding
|
n/a | 139.7 | 139.7 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 14.5 | 195.0 | 209.6 |
| CF Depreciation | 29.7 | 1.4 | 31.1 |
| CF Deferred Taxes | 0.9 | 33.2 | 34.1 |
| Other Non-Cash Items | 7.5 | 9.1 | 16.5 |
| Change in Working Capital | -27.1 | -41.6 | -68.7 |
| Total Cash From Operating Activities | 25.5 | 200.8 | 226.3 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -29.3 | 0.0 | -29.3 |
| Other Investing Cash Flows | -55.7 | 14.4 | -41.3 |
| Total Cash From Investing Activities | -85.0 | 7.0 | -78.0 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | n/a | -83.8 | -83.8 |
| Purchase Or Sale of Stock | -5.2 | n/a | -5.2 |
| Purchase and Retirement of Debt | n/a | 126.5 | 126.5 |
| Other Financing Cash Flow | 0.3 | -90.6 | -90.3 |
| Total Cash From Financing Activities | -4.9 | -193.1 | -198.0 |
| Exchange Rate Effects | -8.2 | n/a | -8.2 |
| Net Change in Cash | -72.6 | 14.7 | -57.9 |
| Cash Taxes Paid | 22.7 | 0.0 | 22.7 |
| Cash Interest Paid | 0.4 | 0.0 | 0.4 |